Acrivon Therapeutics (ACRV)
Market Price (5/30/2026): $1.615 | Market Cap: $62.5 MilSector: Health Care | Industry: Biotechnology
Acrivon Therapeutics (ACRV)
Market Price (5/30/2026): $1.615Market Cap: $62.5 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -154% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Personalized Diagnostics, Show more. | Weak multi-year price returns2Y Excs Rtn is -124%, 3Y Excs Rtn is -170% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -82 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -129% Key risksACRV key risks include [1] its critical dependence on the clinical trial success and regulatory approval of its lead candidates, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -154% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Personalized Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -124%, 3Y Excs Rtn is -170% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -82 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -129% |
| Key risksACRV key risks include [1] its critical dependence on the clinical trial success and regulatory approval of its lead candidates, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 5/26/2026
Acrivon Therapeutics (ACRV) stock has lost about 10% since 1/31/2026 because of the following key factors:
1. Persistent Operating Losses and Pre-Revenue Status.
Acrivon Therapeutics, a clinical-stage company, consistently reported net losses without generating revenue during the specified period. For the fourth quarter of 2025, the company reported a net loss of $19.0 million. This trend continued into the first quarter of 2026, with another net loss of $19.0 million. While the Q1 2026 net loss was slightly lower than the $19.7 million recorded in Q1 2025, the ongoing lack of revenue generation and recurring losses, though typical for a biotech at this stage, can contribute to downward pressure on stock performance.
2. Ongoing Need for Capital and Share Dilution.
The company's operations continue to be reliant on external funding. As of March 31, 2026, Acrivon Therapeutics had cash, cash equivalents, and marketable securities totaling $97.7 million, supplemented by $7.3 million from subsequent equity financing. This capital is projected to fund operations into the third quarter of 2027. The recent equity financing indicates an ongoing need for capital, which can lead to dilution of existing shares and exert downward pressure on the stock price.
Show more
Acrivon Therapeutics (ACRV) stock has lost about 10% since 1/31/2026 because of the following key factors:
1. Persistent Operating Losses and Pre-Revenue Status.
Acrivon Therapeutics, a clinical-stage company, consistently reported net losses without generating revenue during the specified period. For the fourth quarter of 2025, the company reported a net loss of $19.0 million. This trend continued into the first quarter of 2026, with another net loss of $19.0 million. While the Q1 2026 net loss was slightly lower than the $19.7 million recorded in Q1 2025, the ongoing lack of revenue generation and recurring losses, though typical for a biotech at this stage, can contribute to downward pressure on stock performance.
2. Ongoing Need for Capital and Share Dilution.
The company's operations continue to be reliant on external funding. As of March 31, 2026, Acrivon Therapeutics had cash, cash equivalents, and marketable securities totaling $97.7 million, supplemented by $7.3 million from subsequent equity financing. This capital is projected to fund operations into the third quarter of 2027. The recent equity financing indicates an ongoing need for capital, which can lead to dilution of existing shares and exert downward pressure on the stock price.
Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -10.6% change in ACRV stock from 1/31/2026 to 5/29/2026 was primarily driven by a -0.4% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312026 | 5292026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.79 | 1.60 | -10.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 39 | 39 | -0.4% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2026 to 5/29/2026| Return | Correlation | |
|---|---|---|
| ACRV | -10.6% | |
| Market (SPY) | 9.6% | 39.9% |
| Sector (XLV) | -3.0% | 11.1% |
Fundamental Drivers
The -19.6% change in ACRV stock from 10/31/2025 to 5/29/2026 was primarily driven by a -0.7% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 10312025 | 5292026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.99 | 1.60 | -19.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 38 | 39 | -0.7% |
| Cumulative Contribution | 0.0% |
Market Drivers
10/31/2025 to 5/29/2026| Return | Correlation | |
|---|---|---|
| ACRV | -19.6% | |
| Market (SPY) | 11.5% | 27.9% |
| Sector (XLV) | 4.5% | 21.7% |
Fundamental Drivers
The 14.3% change in ACRV stock from 4/30/2025 to 5/29/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302025 | 5292026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.40 | 1.60 | 14.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 38 | 39 | -1.2% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2025 to 5/29/2026| Return | Correlation | |
|---|---|---|
| ACRV | 14.3% | |
| Market (SPY) | 38.0% | 25.8% |
| Sector (XLV) | 8.3% | 23.7% |
Fundamental Drivers
The -87.0% change in ACRV stock from 4/30/2023 to 5/29/2026 was primarily driven by a -43.4% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 4302023 | 5292026 | Change |
|---|---|---|---|
| Stock Price ($) | 12.31 | 1.60 | -87.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 22 | 39 | -43.4% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2023 to 5/29/2026| Return | Correlation | |
|---|---|---|
| ACRV | -87.0% | |
| Market (SPY) | 89.0% | 24.7% |
| Sector (XLV) | 17.7% | 21.2% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ACRV Return | - | -31% | -57% | 22% | -60% | -32% | -90% |
| Peers Return | 6% | -56% | 27% | -44% | 19% | 65% | -36% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 101% |
Monthly Win Rates [3] | |||||||
| ACRV Win Rate | - | 0% | 33% | 50% | 67% | 20% | |
| Peers Win Rate | 50% | 33% | 50% | 37% | 43% | 56% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| ACRV Max Drawdown | - | - | -84% | -49% | -85% | -57% | |
| Peers Max Drawdown | -48% | -78% | -60% | -68% | -65% | -37% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ZNTL, APRE, IDYA, TNGX, ORIC.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/29/2026 (YTD)
How Low Can It Go
In The Past
Acrivon Therapeutics's stock fell -2.4% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 2.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
In The Past
Acrivon Therapeutics's stock fell -2.4% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 2.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Acrivon Therapeutics (ACRV)
We are a clinical stage biopharmaceutical company developing precision oncology medicines that we match to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing our proprietary proteomics-based patient responder identification platform. Recently approved targeted oncology treatments, such as kinase inhibitors, have transformed the cancer treatment landscape, and while the therapeutic benefit of these agents has provided significant benefit to patients, these targeted oncology treatments unfortunately only address the less than 10% of patients with cancers that harbor certain easily-identifiable genetic mutations. Our approach is designed to overcome the limitations of genomics-based patient selection methods. We do this by using our proprietary precision medicine platform, Acrivon Predictive Precision Proteomics, or AP3, to develop our pipeline of oncology drug candidates. Our AP3 platform enables the creation of drug-specific proprietary OncoSignature companion diagnostics that are used to identify the patients most likely to benefit from our drug candidates, which we refer to as patient responders. We are currently advancing our lead candidate, ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 with sub single-digit nM and single-digit nM potency, respectively, in a potentially registrational Phase 2 trial across multiple tumor types, which our AP3 platform predicts will have a high proportion of patient responders based on OncoSignature-predicted sensitivity to ACR-368. Our ACR-368 OncoSignature test, which has not yet obtained regulatory approval, has been extensively evaluated in preclinical studies, including in two separate, blinded, prospectively-designed studies on pretreatment tumor biopsies collected from patients with ovarian cancer treated with ACR-368 in past Phase 2 clinical trials conducted by Eli Lilly and Company, or Lilly, and at the National Cancer Institute, or NCI, demonstrating robust enrichment of responders through our method. The AP3 approach is proteomics-based and designed to enable identification and treatment of the patients whose tumors are sensitive to a specific drug or drug candidate based on direct protein measurement of critical tumor-driving mechanisms and independent of underlying genetic alterations. We believe our approach is applicable across stages of drug development and across therapeutic modalities. Accordingly, the AP3 method is not limited to the typically very small subset of cancers driven by single gene driver mutations or susceptible to a synthetic lethal approach. Rather, we believe our method is broadly applicable to the vast majority of cancers, in particular the majority of solid tumors, for which genetics-based approaches have proven insufficient to identify patient responders in many cases. In principle, we believe a much larger percentage of tumors can be addressed therapeutically using agents attuned to the specific biochemical signaling pathways found in these tumors, which our AP3 platform was purposefully designed to enable. By applying our highly specific patient selection approach to drug development, we seek to both accelerate clinical development and significantly increase the probability of successful treatment outcomes for patients. Our pipeline includes the Phase 2 lead program, ACR-368, also known as prexasertib, a targeted oncology asset that targets CHK1 and CHK2, or CHK1/2. ACR-368 has been dosed in more than 400 patients at the recommended Phase 2 dose, or RP2D, with reported deep, durable responses, including complete responses, or CRs, in a proportion of patients with solid tumors in past single center and multi-center Phase 2 clinical trials in tumor indications with high unmet need. ACR-368 has also demonstrated a favorable safety and tolerability profile with primarily reversible hematological toxicity and very limited non-hematological toxicity. We have received clearance from the U.S. Food and Drug Administration, or FDA, for an Investigational New Drug, or IND, application to advance ACR-368 in Phase 2 single arm clinical trials conducted under the FDA program known as the master protocol, which was developed to help expedite drug development in multiple tumor types for drugs with an established RP2D within the same overall trial structure. Initially, patients with platinum-resistant ovarian, endometrial, or bladder cancer will be treated in this trial. Patients will be stratified for treatment based on OncoSignature-predicted sensitivity to ACR-368 across multiple sites in the United States in this trial with registrational intent. Through the use of our OncoSignature test, we believe we can significantly increase the overall response rate, or ORR, observed in previous trials that were conducted without a prospective patient responder identification method. We also plan to study ACR-368 in additional indications, such as human papilloma virus positive, or HPV+, squamous cell carcinomas, including squamous cell cancer, or SCC, of head and neck, or SCCHN, anal, and cervical cancer, based on demonstrated clinical single agent activity in SCCHN and anal cancer and OncoSignature-based prediction of sensitivity to ACR-368 in a proportion of patients. In addition to ACR-368, we are also developing internally-discovered preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response, or DDR, and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase. We were incorporated under the laws of the State of Delaware in March 2018. Our principal executive offices are located at 480 Arsenal Way, Suite 100, Watertown, Massachusetts.
AI Analysis | Feedback
Here are 1-3 brief analogies for Acrivon Therapeutics:- Acrivon Therapeutics is like 23andMe for cancer treatment, but instead of using DNA to understand inherited risks, they use protein analysis to precisely match patients with the right drugs for their tumor.
- Acrivon is like Waze for cancer drug development, using real-time molecular insights (proteins) to find the most efficient path for a drug to reach the right patients, rather than relying on older, static maps (genetics).
AI Analysis | Feedback
- ACR-368 (Prexasertib): A clinical-stage small molecule inhibitor targeting CHK1 and CHK2, currently in a potentially registrational Phase 2 trial for various solid tumors.
- Acrivon Predictive Precision Proteomics (AP3) Platform: A proprietary proteomics-based platform used to identify patient responders for oncology drug candidates and create drug-specific OncoSignature companion diagnostics.
AI Analysis | Feedback
As a clinical-stage biopharmaceutical company, Acrivon Therapeutics (ACRV) is currently focused on the development of precision oncology medicines and companion diagnostics, advancing its lead candidate, ACR-368, through Phase 2 clinical trials. At this stage of development, the company does not have commercial products on the market.
Therefore, Acrivon Therapeutics does not currently have major customers that purchase its products or services.
AI Analysis | Feedback
nullAI Analysis | Feedback
nullAI Analysis | Feedback
The key risks to Acrivon Therapeutics' business are:
- Clinical Trial Success and Regulatory Approval of Lead Drug Candidate (ACR-368): Acrivon is a clinical-stage biopharmaceutical company, and the success of its lead candidate, ACR-368, in its ongoing "potentially registrational Phase 2 trial" is paramount. There is inherent risk in drug development, and failure to achieve favorable results in clinical trials or to obtain regulatory approval from bodies like the FDA would significantly impact the company's ability to commercialize its primary asset.
- Regulatory Approval and Efficacy of the AP3 Platform and OncoSignature Companion Diagnostics: Acrivon's core strategy relies on its proprietary proteomics-based patient responder identification platform (AP3) and its drug-specific OncoSignature companion diagnostics. The company explicitly states that its "ACR-368 OncoSignature test... has not yet obtained regulatory approval." The successful development, validation, and regulatory approval of this companion diagnostic are critical to its precision medicine approach and its ability to identify patient responders, which it believes will increase overall response rates and accelerate clinical development. Failure to secure regulatory approval for this platform or if it does not perform as anticipated in identifying sensitive patients, would undermine its entire business model and pipeline.
AI Analysis | Feedback
The primary clear emerging threat for Acrivon Therapeutics is the regulatory approval and prospective clinical validation of its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), and its associated OncoSignature companion diagnostic. The company explicitly states that the "ACR-368 OncoSignature test, which has not yet obtained regulatory approval." The success of their lead candidate, ACR-368, in its potentially registrational Phase 2 trial is contingent upon this OncoSignature test successfully identifying patient responders and receiving regulatory approval. A failure to secure regulatory approval for the diagnostic, or if the AP3 platform and OncoSignature test fail to demonstrate robust prospective predictive power and patient enrichment in the ongoing registrational-intent clinical trials, would undermine Acrivon Therapeutics' core precision oncology strategy and its ability to bring its drug candidates to market as intended.
AI Analysis | Feedback
nullAI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Acrivon Therapeutics (ACRV) over the next 2-3 years:
- Advancement and potential regulatory approval of ACR-368 (prexasertib) for initial indications: Acrivon is currently advancing its lead candidate, ACR-368, in a potentially registrational Phase 2 trial for patients with platinum-resistant ovarian, endometrial, or bladder cancer. Successful completion of this trial and subsequent regulatory approval would be a primary driver of revenue growth as the company could begin commercializing the drug in these high-unmet-need indications.
- Expansion of ACR-368 into additional tumor types: Beyond its initial registrational trial, Acrivon plans to study ACR-368 in additional indications, such as human papilloma virus positive (HPV+) squamous cell carcinomas, including head and neck (SCCHN), anal, and cervical cancer. Successful clinical development and eventual approval in these expanded markets would significantly broaden the patient population and potential revenue streams for ACR-368.
- Commercialization and adoption of the proprietary OncoSignature companion diagnostic: Integral to Acrivon's strategy is its proprietary proteomics-based patient responder identification platform, AP3, which enables the creation of drug-specific OncoSignature companion diagnostics. The successful development, regulatory approval, and widespread adoption of the ACR-368 OncoSignature test are crucial for identifying patient responders and maximizing the efficacy and market potential of ACR-368, indirectly driving drug revenue and potentially generating revenue from the diagnostic itself.
- Strategic partnerships and collaborations: As Acrivon progresses its lead candidate ACR-368 and its innovative AP3 platform, the company may pursue strategic partnerships or collaborations. These could involve licensing agreements for specific regions, co-development deals, or partnerships to apply the AP3 platform to other drug candidates, generating revenue through upfront payments, milestone achievements, and royalties.
AI Analysis | Feedback
Share Issuance
- Acrivon Therapeutics priced its initial public offering on November 14, 2022, offering 7,550,000 shares of common stock at a price of $12.50 per share.
- Concurrently with the IPO in November 2022, the company sold an additional 400,000 shares of common stock to an existing stockholder, Chione Limited, through a private placement. The gross proceeds from the IPO and this concurrent private placement were approximately $99.4 million.
- In April 2024, Acrivon completed a private investment in public equity (PIPE) financing, issuing 8,235,000 shares of common stock at $8.50 per share and pre-funded warrants for up to 7,060,000 shares at $8.499 per warrant, raising approximately $130 million in gross proceeds.
Inbound Investments
- Prior to its IPO in November 2022, Acrivon Therapeutics secured $100 million in an oversubscribed Series B financing round in November 2021.
- The company completed a private investment in public equity (PIPE) financing in April 2024, with new and existing accredited investors providing approximately $130 million in gross proceeds.
Capital Expenditures
- Acrivon Therapeutics invested $899K in capital expenditures in Q3 2025, primarily funding long-term assets and infrastructure.
- Capital expenditures for the 12 months prior to Q3 2025 amounted to $2.28 million.
- The company anticipates that its cash, cash equivalents, and investments are sufficient to fund operating expenses and capital expenditure requirements into the second quarter of 2027.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Acrivon Therapeutics Earnings Notes | 12/16/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to ACRV.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 6.22 |
| Mkt Cap | 0.6 |
| Rev LTM | 0 |
| Op Inc LTM | -131 |
| FCF LTM | -100 |
| FCF 3Y Avg | -121 |
| CFO LTM | -98 |
| CFO 3Y Avg | -120 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 39.0% |
| Rev Chg 3Y Avg | 515.8% |
| Rev Chg Q | -100.0% |
| QoQ Delta Rev Chg LTM | -2.8% |
| Op Inc Chg LTM | 18.5% |
| Op Inc Chg 3Y Avg | -10.6% |
| Op Mgn LTM | -143.8% |
| Op Mgn 3Y Avg | -1,192.8% |
| QoQ Delta Op Mgn LTM | -18.2% |
| CFO/Rev LTM | -143.3% |
| CFO/Rev 3Y Avg | -926.8% |
| FCF/Rev LTM | -144.6% |
| FCF/Rev 3Y Avg | -941.1% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.6 |
| P/S | 33.5 |
| P/Op Inc | -3.9 |
| P/EBIT | -3.9 |
| P/E | -4.4 |
| P/CFO | -5.1 |
| Total Yield | -29.7% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -56.2% |
| D/E | 0.0 |
| Net D/E | -0.5 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 0.3% |
| 3M Rtn | 1.7% |
| 6M Rtn | -23.1% |
| 12M Rtn | 46.2% |
| 3Y Rtn | -20.8% |
| 1M Excs Rtn | -5.9% |
| 3M Excs Rtn | -8.5% |
| 6M Excs Rtn | -33.6% |
| 12M Excs Rtn | 19.3% |
| 3Y Excs Rtn | -103.3% |
Price Behavior
Price Behavior
| Market Price | $1.60 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 11/15/2022 | |
| Distance from 52W High | -46.8% | |
| 50 Days | 200 Days | |
| DMA Price | $1.73 | $1.84 |
| DMA Trend | up | up |
| Distance from DMA | -7.3% | -13.2% |
| 3M | 1YR | |
| Volatility | 72.1% | 93.0% |
| Downside Capture | 255.61 | 256.64 |
| Upside Capture | 183.51 | 223.30 |
| Correlation (SPY) | 44.7% | 27.5% |
ACRV Betas & Captures as of 4/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.09 | 2.34 | 2.29 | 2.15 | 1.90 | 1.68 |
| Up Beta | 2.70 | 2.89 | 2.93 | 2.53 | 1.34 | 1.70 |
| Down Beta | 14.07 | 2.91 | 0.97 | 1.04 | 2.14 | 1.76 |
| Up Capture | 359% | 268% | 263% | 309% | 302% | 120% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 16 | 24 | 30 | 61 | 116 | 341 |
| Down Capture | 347% | 147% | 222% | 199% | 166% | 112% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 5 | 18 | 32 | 60 | 117 | 385 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ACRV | |
|---|---|---|---|---|
| ACRV | 50.4% | 92.9% | 0.86 | - |
| Sector ETF (XLV) | 15.8% | 14.6% | 0.78 | 20.8% |
| Equity (SPY) | 30.3% | 11.8% | 1.94 | 27.2% |
| Gold (GLD) | 37.5% | 26.7% | 1.17 | 5.7% |
| Commodities (DBC) | 39.6% | 18.8% | 1.63 | -9.6% |
| Real Estate (VNQ) | 12.5% | 13.1% | 0.64 | 10.5% |
| Bitcoin (BTCUSD) | -31.8% | 41.6% | -0.81 | 19.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ACRV | |
|---|---|---|---|---|
| ACRV | -37.0% | 104.1% | -0.14 | - |
| Sector ETF (XLV) | 5.4% | 14.7% | 0.19 | 18.0% |
| Equity (SPY) | 14.3% | 17.0% | 0.66 | 22.6% |
| Gold (GLD) | 18.8% | 18.0% | 0.85 | 6.5% |
| Commodities (DBC) | 10.2% | 19.4% | 0.41 | 1.7% |
| Real Estate (VNQ) | 3.4% | 18.8% | 0.08 | 16.9% |
| Bitcoin (BTCUSD) | 14.6% | 54.6% | 0.46 | 10.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ACRV | |
|---|---|---|---|---|
| ACRV | -20.6% | 104.1% | -0.14 | - |
| Sector ETF (XLV) | 9.9% | 16.5% | 0.49 | 18.0% |
| Equity (SPY) | 15.9% | 17.9% | 0.76 | 22.6% |
| Gold (GLD) | 13.3% | 16.0% | 0.69 | 6.5% |
| Commodities (DBC) | 7.3% | 17.9% | 0.33 | 1.7% |
| Real Estate (VNQ) | 5.7% | 20.7% | 0.24 | 16.9% |
| Bitcoin (BTCUSD) | 67.0% | 66.9% | 1.06 | 10.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated N/A/N/A/N/A| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/13/2026 | 0.0% | -8.3% | |
| 3/19/2026 | 3.7% | -7.3% | 8.5% |
| 1/8/2026 | -34.6% | -38.0% | -43.4% |
| 11/13/2025 | 8.2% | 9.2% | 16.9% |
| 8/13/2025 | 6.1% | -0.8% | 16.0% |
| 5/14/2025 | -3.5% | 0.9% | 5.3% |
| 3/25/2025 | -51.6% | -68.8% | -63.1% |
| 11/13/2024 | -5.5% | -24.0% | -16.3% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 8 | 6 | 6 |
| # Negative | 7 | 9 | 8 |
| Median Positive | 6.4% | 6.3% | 16.5% |
| Median Negative | -5.5% | -8.3% | -13.9% |
| Max Positive | 10.6% | 10.9% | 30.9% |
| Max Negative | -51.6% | -68.8% | -63.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/13/2026 | 10-Q |
| 12/31/2025 | 03/19/2026 | 10-K |
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/13/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 03/27/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 03/28/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/11/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/28/2023 | 10-K |
| 09/30/2022 | 12/15/2022 | 10-Q |
| 06/30/2022 | 11/16/2022 | 424B4 |
Recent Forward Guidance
Updated 5/28/2026Latest: Q1 2026 Earnings Reported 5/13/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q3 2027 Cash Runway | 3 | ||||||
Insider Activity
Updated 5/26/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Blume-Jensen, Peter | President and CEO | Direct | Buy | 1162026 | 1.68 | 49,000 | 82,124 | 3,512,512 | Form |
| 2 | Levy, Adam D | Chief Financial Officer | Direct | Buy | 1162026 | 1.70 | 8,832 | 14,999 | 35,635 | Form |
| 3 | Devroe, Eric | Chief Operating Officer | Direct | Buy | 1152026 | 1.72 | 10,000 | 17,218 | 129,665 | Form |
| 4 | Perceptive, Advisors Llc | See Footnote | Sell | 5012025 | 1.34 | 298,886 | 400,507 | 4,159,546 | Form | |
| 5 | Perceptive, Advisors Llc | See Footnote | Sell | 5012025 | 1.41 | 437,881 | 617,412 | 4,798,265 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 5/29/2026